Literature DB >> 10830241

Tacrolimus and myocardial hypertrophy.

Y Nakata1, M Yoshibayashi, T Yonemura, S Uemoto, Y Inomata, K Tanaka, K Furusho.   

Abstract

Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac wall thickening. Our findings demonstrated that tacrolimus-induced myocardial hypertrophy correlated with tacrolimus blood levels, and that myocardial hypertrophy induced by tacrolimus was reversible. However, no patients developed clinically significant symptoms related to myocardial hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830241     DOI: 10.1097/00007890-200005150-00039

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients.

Authors:  G V Mazariegos; A A Salzedas; A Jain; J Reyes
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Different influences on tacrolimus pharmacokinetics by coadministrations of zhi ke and zhi shi in rats.

Authors:  Shiuan-Pey Lin; Ping-Ping Wu; Yu-Chi Hou; Shang-Yuan Tsai; Meng-Ju Wang; Shih-Hua Fang; Pei-Dawn Lee Chao
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-20       Impact factor: 2.629

Review 3.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Blood concentration of tacrolimus and age predict tacrolimus-induced left ventricular dysfunction after bone marrow transplantation in adults.

Authors:  Kohko Kanazawa; Masumi Iwai-Takano; Satoru Kimura; Tetsuya Ohira
Journal:  J Med Ultrason (2001)       Date:  2019-12-02       Impact factor: 1.314

5.  Cardiac changes noted within 4 years of transplant in postmortem evaluation of a patient with untreated obstructive sleep apnea.

Authors:  Nancy F Fishback; George R Wettach
Journal:  Sleep Breath       Date:  2004-06       Impact factor: 2.816

Review 6.  Tacrolimus: a further update of its use in the management of organ transplantation.

Authors:  Lesley J Scott; Kate McKeage; Susan J Keam; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Clinical aspects of tacrolimus use in paediatric renal transplant recipients.

Authors:  Agnieszka Prytuła; Teun van Gelder
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

8.  Pulmonary hypertension and cardiac hypertrophy in children recipients of orthotopic living related liver transplantation.

Authors:  Magd A Kotb; Inas Abd El Satar; Ahmed M Badr; Nancy H Anis; Hoda Abd El Rahman Ismail; Alaa F Hamza; Hesham M Abdelkader
Journal:  J Adv Res       Date:  2017-07-27       Impact factor: 10.479

Review 9.  Cardiovascular effects of immunosuppression agents.

Authors:  Aly Elezaby; Ryan Dexheimer; Karim Sallam
Journal:  Front Cardiovasc Med       Date:  2022-09-21

10.  Formulation strategies for drug delivery of tacrolimus: An overview.

Authors:  Pranav Patel; Hitesh Patel; Shital Panchal; Tejal Mehta
Journal:  Int J Pharm Investig       Date:  2012-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.